ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis

NAActive, not recruitingINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

September 18, 2018

Primary Completion Date

October 2, 2020

Study Completion Date

July 31, 2030

Conditions
Aortic Valve Stenosis
Interventions
DEVICE

TAVR with CENTERA THV

TAVR with the Edwards CENTERA THV System

Trial Locations (23)

10032

Columbia University Medical Center/ NYPH, New York

15212

Allegheny - Singer Research Institute, Pittsburgh

19104

University of Pennsylvania, Philadelphia

20010

Washington Hospital Center, Washington D.C.

30308

Emory University, Atlanta

34239

Sarasota Memorial Hospital, Sarasota

37205

Saint Thomas Health, Nashville

43214

The Ohio Health Research Institute, Columbus

46290

St. Vincent Medical Group, Inc./St. Vincent Heart Center of Indiana, LLC, Indianapolis

48202

Henry Ford Hospital, Detroit

63110

Washington University/ Barnes-Jewish Hospital, St Louis

66160

University of Kansas Health System, Kansas City

67226

Cardiovascular Research Institute of Kansas, Wichita

75093

The Heart Hospital Baylor Plano, Plano

75226

Baylor Heart and Vascular Hospital, Dallas

76508

Baylor Scott and White, Central Texas, Temple

77030

The University of Texas Health Science Center at Houston, Houston

University of Texas Memorial Hermann, Houston

80538

UC Health Northern Colorado (Medical Center of the Rockies), Loveland

90048

Cedars-Sinai Medical Center, Los Angeles

94305

Stanford University Medical Center, Stanford

02115

Brigham and Women's Hospital, Boston

07960

Atlantic Health System Hospital Corp, Morristown

Sponsors
All Listed Sponsors
lead

Edwards Lifesciences

INDUSTRY